Accelerate Diagnostics (NASDAQ:AXDX) Now Covered by Analysts at StockNews.com

Equities researchers at StockNews.com started coverage on shares of Accelerate Diagnostics (NASDAQ:AXDXGet Free Report) in a note issued to investors on Tuesday. The firm set a “hold” rating on the medical research company’s stock.

Separately, BTIG Research upgraded Accelerate Diagnostics to a “strong-buy” rating in a report on Wednesday, December 11th.

View Our Latest Research Report on Accelerate Diagnostics

Accelerate Diagnostics Stock Performance

AXDX opened at $1.31 on Tuesday. Accelerate Diagnostics has a one year low of $0.73 and a one year high of $2.09. The business’s 50 day moving average price is $1.30 and its 200 day moving average price is $1.54. The stock has a market capitalization of $32.80 million, a PE ratio of -0.46 and a beta of 0.59.

Insider Buying and Selling at Accelerate Diagnostics

In other Accelerate Diagnostics news, Director John Patience acquired 200,000 shares of the company’s stock in a transaction dated Tuesday, December 3rd. The stock was acquired at an average cost of $1.57 per share, with a total value of $314,000.00. Following the purchase, the director now directly owns 653,224 shares in the company, valued at approximately $1,025,561.68. This trade represents a 44.13 % increase in their position. The acquisition was disclosed in a filing with the SEC, which is available through this link. 43.60% of the stock is owned by company insiders.

Hedge Funds Weigh In On Accelerate Diagnostics

A hedge fund recently bought a new stake in Accelerate Diagnostics stock. Y Intercept Hong Kong Ltd purchased a new position in Accelerate Diagnostics, Inc. (NASDAQ:AXDXFree Report) during the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm purchased 19,866 shares of the medical research company’s stock, valued at approximately $34,000. Y Intercept Hong Kong Ltd owned about 0.08% of Accelerate Diagnostics as of its most recent filing with the Securities and Exchange Commission. Hedge funds and other institutional investors own 17.14% of the company’s stock.

Accelerate Diagnostics Company Profile

(Get Free Report)

Accelerate Diagnostics, Inc, an in vitro diagnostics company, provides solutions for the diagnosis of serious infections in the United States, Europe, and the Middle East. The company offers Accelerate Pheno system, an in vitro diagnostic platform for the identification and antibiotic susceptibility testing of pathogens associated with serious or health care-associated infections, including gram-positive and gram-negative organisms.

Featured Stories

Receive News & Ratings for Accelerate Diagnostics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Accelerate Diagnostics and related companies with MarketBeat.com's FREE daily email newsletter.